Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab for monoclonal gammopathies of renal significance in Finland
2021-005856-12Phase 2Active
- Sponsor
- Helsinki University Hospital
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in Paraprotein-associated kidney disease (PAKD), sponsored by Helsinki University Hospital. Primary endpoints: Renal and hematological endpoints at end of treatment and Rate of renal remission at end of treatment. Started Nov 2021; status: active.
02
Drugs
daratumumab
03
Conditions
Paraprotein-associated kidney disease (PAKD)
Beyond the preview
Go deeper on 2021-005856-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005856-12.